Premium
Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation
Author(s) -
Harel Efrat,
Shoji Jun,
Abraham Vivek,
Miller Loan,
Laszik Zoltan,
Thurison Tine,
King Andrew,
Olshen Adam,
Leung Joey,
Szabo Gyula,
Hann Byron,
HøyerHansen Gunilla,
Craik Charles S.,
Vincenti Flavio
Publication year - 2019
Publication title -
clinical transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 76
eISSN - 1399-0012
pISSN - 0902-0063
DOI - 10.1111/ctr.13487
Subject(s) - medicine , urokinase receptor , transplantation , biomarker , focal segmental glomerulosclerosis , urology , supar , glomerulosclerosis , kidney transplantation , endocrinology , gastroenterology , pathology , glomerulonephritis , proteinuria , receptor , kidney , biology , biochemistry
Background We investigated circulating levels of individual soluble urokinase plasminogen activation receptor (su PAR ) forms to determine if specific circulating fragments of su PAR ( II ‐ III ) and (I) can better serve as clinical biomarkers for focal segmental glomerulosclerosis ( FSGS ) and the risk of recurrence after transplantation. Materials and Methods Serum levels of intact su PAR and its cleaved forms were measured with two assays, ELISA and TR ‐ FIA . Results su PAR levels in healthy controls were significantly lower than those who had glomerular diseases but were not significantly different between FSGS patients and glomerular controls. Intact su PAR (I‐ II ‐ III ) levels were noted to be elevated in glomerular diseases including FSGS . u PAR fragment (I) levels measured with the TR ‐ FIA 4 assay were significantly higher in FSGS (695.4 + 91.29 pMol/L) than glomerular controls (239.1 + 40.45 pMol/L, P = 0.001). However, su PAR (I) levels were not significantly different between recurrent FSGS and nonrecurrent FSGS patients. Conclusion Our analysis of su PAR using the ELISA assay used in all previous studies does not appear to be a useful marker for FSGS nor serve as a predictor for its recurrence after transplantation. The TR ‐ FIA assay results suggest that uPAR (I) is a potential biomarker for FSGS but not of its recurrence.